logo-loader
viewHikma Pharmaceuticals plc.

Hikma in nasal spray licence agreement, full-year profits soar

The firm said it is not experiencing disruption from the coronavirus outbreak while profits soared in 2019

Hikma Pharmaceuticals plc. -

Hikma Pharmaceuticals PLC (LON:HIK) has signed an exclusive licence agreement with Glenmark Pharmaceuticals to commercialise Ryaltris in the US.

Under the deal, Glenmark will develop the treatment, which is a nasal spray for the treatment of seasonal allergic rhinitis, and submit it for approval to the Food and Drug Administration.

READ: Hikma hurt by JP Morgan downgrade to ‘underweight’

Hikma will then commercialise it once it receives the green light from the authorities.

The FTSE 100-listed firm will give Glenmark an upfront payment, regulatory approval and commercial milestone payments as well as royalties.

No coronavirus disruption

In a separate announcement, the pharma giant set out guidance for 2020 alongside results for the year to 31 December.

The firm added it is currently not experiencing any disruption from the coronavirus outbreak as it does not have “extensive” operations in China.

Revenues for the injectables and branded divisions are expected to grow in the mid-single digits, while generics will deliver sales between US$700mln and US$750mln.

The figures assume the launch of asthma treatment Advair Diskus in the second half of the year, estimated to generate sales of US$20-40mln.

Soaring profits

In 2019, profit before tax soared 40% to US$491mln thanks to "better-managed inventory expenses" driving operating profit in the generics division, which accounted for a third of total revenue, up 278%.

The injectables division, half of total sales, delivered a 5% increase in operating profits, while the branded division, a quarter of total revenue, dipped 5%.

Group revenue was up 7% to US$2.2bn. Sales in the injectables, generics and branded divisions rose 5%, 4% and 7% respectively to US$890mln, US$719mln and US$583mln respectively.

During the year, Hikma launched 108 new products and received 169 approvals.

The total dividend was raised by 14% to US$44 cents per share.

Shares advanced 4% to 1,900.89p on Thursday morning.

--Adds detail--

Quick facts: Hikma Pharmaceuticals plc.

Price: 2207 GBX

AIM:HIK
Market: AIM
Market Cap: £5.35 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioCorRx says COVID-19 will not delay their work on...

BioCorRx (OTCMKTS: BICX) CEO Brady Granier joined Steve Darling from Proactive in Vancouver to discuss if their business and research are being affected by the outbreak of COVID-19. Granier telling Proactive some of the ways the company is able to continue their works especially when it...

14 hours, 23 minutes ago

2 min read